SARS-CoV-2-specific ELISA development
SARS-CoV-2-specific ELISA development
复制标题
DOI：
10.1016/j.jim.2020.112832
复制
发表时间：
2020-09-01
影响因子：
2.2
通讯作者：
Alter, Galit
中科院分区：
文献类型：
--
作者：
Roy, Vicky;Fischinger, Stephanie;Alter, Galit
管理COVID-19传播的关键是能够诊断感染并确定整个人群的获得性免疫反应。虽然新型几种急性呼吸道综合征冠状病毒2型（SARS-CoV-2）的基因组检测在有限的时间范围内检测病毒RNA的存在，但当病毒在上呼吸道脱落时，迫切需要能够在可检测病毒复制的短窗口之外确定暴露和感染的测试。感染后，抗体在几天内产生，提供持久的读数和暴露和感染的档案。已经出现了几种抗体测试来诊断SARS-CoV-2。在这里，我们报告了一个合格的定量ELISA检测，显示所有必要的高通量样品分析的特点。总的来说，这项测试提供了一个定量的机会，以确定暴露和免疫水平的SARS-CoV-2。
Critical to managing the spread of COVID-19 is the ability to diagnose infection and define the acquired immune response across the population. While genomic tests for the novel Several Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) detect the presence of viral RNA for a limited time frame, when the virus is shed in the upper respiratory tract, tests able to define exposure and infection beyond this short window of detectable viral replication are urgently needed. Following infection, antibodies are generated within days, providing a durable read-out and archive of exposure and infection. Several antibody tests have emerged to diagnose SARS-CoV-2. Here we report on a qualified quantitative ELISA assay that displays all the necessary characteristics for high-throughput sample analysis. Collectively, this test offers a quantitative opportunity to define both exposure and levels of immunity to SARS-CoV-2.